QC
AVBP icon

Quadrature Capital’s ArriVent BioPharma AVBP Stock Holding History

Quadrature Capital’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.71M Buy
49,125
+35,818
+269% +$1.06M 0.01% 559
2026
Q1 		$307K Buy
13,307
+544
+4% +$12.3K ﹤0.01% 975
2025
Q4 		$257K Buy
+12,763
New +$266K ﹤0.01% 897

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Quadrature Capital's AVBP Position: Q2 2026 in Review

Quadrature Capital increased its ArriVent BioPharma (AVBP) stake by 269% in Q2 2026, buying an estimated $1.06M and bringing the position to 49,125 shares worth $1.71M. The position accounts for 0.01% of the portfolio, ranked #559.

Quadrature Capital first reported a position in AVBP in Q4 2025 and has held it in 3 quarters since. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Quadrature Capital held 49,125 shares of ArriVent BioPharma worth $1.71M as of Q2 2026.
  • Quadrature Capital bought 35,818 ArriVent BioPharma shares in Q2 2026, an estimated $1.06M.
  • ArriVent BioPharma made up 0.01% of Quadrature Capital's portfolio in Q2 2026, its #559 holding.
  • Quadrature Capital first reported a position in ArriVent BioPharma in Q4 2025 and has held it in 3 quarters since.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.